S

an Diego’s Neurocrine Biosciences on Tuesday just snagged a long-awaited Food and Drug Administration approval for its dopamine-regulating drug, Ingrezza, to treat a movement disorder called tardive dyskinesia. It’s the first drug approved to treat this disorder — and the first drug approved for the company, whose value has swelled past $3.6 billion.

Patients with conditions like bipolar disorder, schizophrenia, and major depression often get prescribed antipsychotic drugs — and tardive dyskinesia shows up as a rather debilitating side effect in about 5 to 8 percent of these people. It consists of uncontrollable, uncoordinated movements of the arms, hands, feet, body — or in facial expressions, such as grimacing, or constant movement of the jaw, tongue, lips, or eyebrows.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.